Boots WebMD Partners in Health
Return To Boots

Diabetes health centre

This article is from the WebMD News Archive

New diabetes drug to be rejected

NICE unable to recommend dapagliflozin (Forxiga) for type 2 diabetes and requests more information from the manufacturer
WebMD UK Health News
Medically Reviewed by Dr Farah Ahmed

1st February 2013 - In draft guidance published today NICE (the National Institute for Health and Clinical Excellence) has said it is minded not to recommend dapagliflozin (Forxiga) in combination therapy for treating type 2 diabetes.

However, before it comes to a final decision, it is requesting further clarification and information from the manufacturers (Bristol-Myers Squibb and Astra Zeneca) ahead of a meeting in April.

New drug

Diabetes currently affects almost three million people in the UK around 90% of which will have type 2 diabetes - a condition that occurs when the body does not produce enough insulin or use insulin properly. Your body needs insulin to be able to use the sugar (glucose) which comes from the food you eat for energy. Without enough insulin, glucose stays in the blood, creating high levels of blood sugar.

Dapagliflozin (Forxiga) is the first in a new class of diabetes drugs. It lowers blood sugar by increasing the amount of glucose excreted in the urine. Dapagliflozin (Forxiga) is administered orally as a single dose of 10 mg per day.

This drug has, so far, been rejected by the US FDA due to concerns about a cancer risk but it has a UK marketing authorisation in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as:

• Monotherapy when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance.

• Add-on combination therapy with other glucose-lowering agents including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.

More information

The latest guidance from NICE was looking at the drug as an add-on combination therapy. However, it was unhappy with the information that was supplied by the manufacturers saying it was concerned about the quality and validity of some of the results. The Appraisal Committee has therefore, requested more information.

Professor Carole Longson, Health Technology Evaluation Centre Director at NICE said in a press statement: "Type 2 diabetes is a serious problem in the UK and it is important that there is a range of different treatment options available. Unfortunately the Appraisal Committee is currently unable to recommend dapagliflozin, one of the options, for the treatment of this condition. They have requested further information from the manufacturer, which will be considered at the next Appraisal Committee meeting in April."

Until NICE issues final guidance, likely to be published in June 2013, NHS bodies should make decisions locally on the funding of specific treatments.

Reviewed on February 01, 2013

Diabetes newsletter

Tips for managing your diabetes.
Sign Up Now!

Popular slideshows & tools on BootsWebMD

man holding back
Myths & facts about back pain
hands grabbing knee
How to keep your joints healthy
bowl of soup
Small changes that lead to weight loss
cute baby
Simple tips to keep baby's skin healthy
cute dog
10 common allergy triggers
Do you know what causes hair loss?
woman exercising
Exercises for low back pain
sperm and egg
Facts to help you get pregnant
bucket with cleaning supplies in it
Cleaning for a healthy home
rash on skin
Soothe skin and prevent flare-ups
mother and child
Could your baby be allergic to milk?
pregnant woman eating healthy salad
Nutrition needs before pregnancy